Viewing Study NCT00441792



Ignite Creation Date: 2024-05-05 @ 5:24 PM
Last Modification Date: 2024-10-26 @ 9:31 AM
Study NCT ID: NCT00441792
Status: COMPLETED
Last Update Posted: 2012-04-11
First Post: 2007-02-27

Brief Title: The Effect of Etomidate on Patient Outcomes After Single Bolus Doses
Sponsor: Advocate Hospital System
Organization: Advocate Hospital System

Study Overview

Official Title: A Randomized Trial of Etomidate Versus Midazolam for Intubation of Patients With Sepsis
Status: COMPLETED
Status Verified Date: 2012-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The primary aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation RSI in the emergency department To achieve this aim we plan to perform a prospective randomized trial measuring the length of stay of patients meeting sepsis criteria and requiring intubation The investigators will compare in-hospital mortality rates between patients given etomidate and patients given midazolam for induction In addition to hospital length of stay secondary endpoints between the two groups will include length of stay in the intensive care unit death within 48 hours of admission and total number of days intubated

Research Hypothesis

In adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation the length of stay of patients given etomidate will be greater than that of patients given the alternative agent midazolam for induction
Detailed Description: Rationale Although the use of the drug etomidate for continuous sedation in mechanically ventilated patients was found to have detrimental effects on patient mortality shortly after its introduction into clinical practice etomidate continues to be widely used as an induction agent for endotracheal intubation Recent data have called into question the safety of using etomidate for even a single bolus in patients at risk of adrenal insufficiency emphasizing the fact that single bolus doses of etomidate cause measurable adrenal suppression and consequently may cause an increase in vasopressor requirements and hospital length of stay Alternative FDA-approved induction agents such as midazolam are claimed by many authors to be safer than etomidate however no studies have formally compared these agents

Research Hypothesis The investigators hypothesize that in critically ill adult patients presenting to the emergency department with sepsis and requiring rapid sequence intubation the hospital length of stay of patients given etomidate will be increased compared to patients given midazolam for induction

Specific Aims The specific aim is to determine the difference in hospital length of stay between septic patients given etomidate and those given midazolam for induction during rapid sequence intubation in the emergency department The investigators plan to compare the two groups in terms of length of hospital stay length of ICU stay and duration of intubation by performing a prospective randomized trial of critically ill patients presenting to the emergency department with sepsis requiring intubation The investigators will also compare the mortality rates in these two groups while controlling for severity of illness and the use of steroids while hospitalized Significance If the use of etomidate to induce anesthesia prior to intubation is found to adversely affect the length of stay of septic patients a reduction in the length of stay in such patients might be achieved by using alternative agents for induction The current widespread use of an induction agent that may adversely affect the length of stay of septic patients has significant implications for patient management

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None